The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program

NCT ID: NCT03253783

Last Updated: 2018-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1304 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2018-01-31

Brief Summary

This study uses a randomized controlled design to evaluate the efficacy of a new mobile app, Pulse, in reducing the incidence of unprotected sex among young women. Pulse is a web-based mobile health application that can be accessed through mobile smartphones and computers. Pulse was designed to increase highly effective birth control use and reproductive and sexual health care utilization, and ultimately decrease teen pregnancy. The sample is comprised of women with the following characteristics at study enrollment: aged 18-20, not pregnant or trying to become pregnant, has daily access to a smartphone, currently living in the United States or a U.S. territory, and speaks either English or Spanish. Most of the sample (at least 70%) will be women who identify as Black and/or Latina. The evaluation team plans to enroll up to 1,300 participants over a one-year enrollment period using social media, including Facebook, Instagram, and Twitter.

Users access Pulse autonomously, on their own terms, and in their own time and place. The app consists of 6 sections and includes 3 hours of unique content. It does not require the user to follow a specific sequence of content viewed; however, all users will receive a monetary incentive after registering with the apps. Youth randomized to the intervention condition are given access to Pulse indefinitely and receive daily text messages related to sexual health for 6 weeks. Control participants are directed to a free general health/fitness web-based mobile application, also called Pulse, and receive text messages related to general health for 6 weeks. The control and treatment apps look and feel similar aesthetically but contain different content. Participants in both the intervention and comparison groups receive a baseline survey and a 6-week follow-up survey. Participants will also receive incentives once they complete the baseline and post-intervention survey. Both surveys are conducted online via an electronic survey platform. This study is being conducted as a Rigorous Evaluation of New or Innovative Approaches to Prevent Teen Pregnancy funded by the U.S. Department of Health and Human Services' Office of Adolescent Health.

Conditions

Unprotected Sex; Contraceptive Usage; Reproductive and Sexual Health Care Utilization

Study Design

• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Interventions

Pulse

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Gender: Female
• Age Limit: 18-20
• Must have daily access to a smartphone that receives text messages and can access to the Internet
• Must speak English or Spanish
• Must live in the United States or a U.S. territory

Exclusion Criteria

• Currently pregnant or trying to get pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 20 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Child Trends

OTHER

Sponsor Role: collaborator

Ewald and Wasserman

UNKNOWN

Sponsor Role: collaborator

Meta Media

UNKNOWN

Sponsor Role: collaborator

Healthy Teen Network

OTHER

Sponsor Role: lead

Responsible Party

Martinez Garcia

Dr. Genevieve Martínez-García

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Genevieve Martinez-Garcia, PhD

Role: PRINCIPAL_INVESTIGATOR

Healthy Teen Network

Jennifer Manlove, PhD

Role: PRINCIPAL_INVESTIGATOR

Child Trends

Locations

Healthy Teen Network

Baltimore, Maryland, United States

Countries

United States

References

Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.

Reference Type: DERIVED

PMID: 32779730 (View on PubMed)

Other Identifiers

TP2AH000038

Identifier Type: -

Identifier Source: org_study_id